Abstract
In 2019, isavuconazole was approved in Brazil by ANVISA for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM). The primary objective was to assess the cost-effectiveness of isavuconazole compared to reference voriconazole for suspected IA in the Brazilian Private Healthcare System (PHS). The secondary objective was to assess the price impact in an economic evaluation of generic voriconazole versus isavuconazole without discount on list price, and generic and reference voriconazole with a 60% discount.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
